Flolan Scleroderma PH Claim Expands Potential Patient Rolls By Over 30,000
This article was originally published in Pharmaceutical Approvals Monthly
The approved patient population for Glaxo Wellcome’s Flolan is expanding by at least 30,000 with the drug’s recent clearance for use in scleroderma patients with pulmonary hypertension, according to Glaxo figures.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class